Dianthus Therapeutics (DNTH) Non Operating Income (2022 - 2025)

Dianthus Therapeutics' Non Operating Income history runs 4 years deep, the most recent figure standing at $3.5 million for Q3 2025.

• On a quarterly basis, Non Operating Income fell 25.45% year-over-year to $3.5 million in Q3 2025; TTM through Sep 2025 was $14.0 million, a 11.69% decrease from a year earlier, with the FY2024 full-year figure at $16.9 million, up 265.77% from the prior year.
• Non Operating Income improved to $3.5 million in Q3 2025 per DNTH's latest filing, from $3.3 million in the prior quarter.
• Across five years, Non Operating Income topped out at $4.7 million in Q3 2024 and bottomed at $470000.0 in Q3 2022.
• The 4-year median for Non Operating Income is $3.3 million (2025), against an average of $2.5 million.
• Across the five-year window, Non Operating Income surged 622.8% in 2024 and fell 28.26% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $577000.0 in 2022, then jumped by 314.73% to $2.4 million in 2023, then surged by 45.26% to $3.5 million in 2024, then gained by 1.35% to $3.5 million in 2025.
• Per Business Quant, the three latest DNTH Non Operating Income figures stand at $3.5 million (Q3 2025), $3.3 million (Q2 2025), and $3.7 million (Q1 2025).